Unanimous vote lights path to FDA approval for LCA gene therapy

All 16 members of the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted to recommend Spark Therapeutic’s Luxterna (voretigene neparvovec) for regulatory approval at a landmark hearing on October 12.
Source: Daily Dose of Eye Care

https://www.lvcenter4sight.com/unanimous-vote-lights-path-to-fda-approval-for-lca-gene-therapy/

Comments

Popular posts from this blog

Week in review: Pay raise, Von’s Vision, gonio-<em>what?</em>

Patch with Microneedles Could Replace Eye Injections

Incidence of eyelid SCC appears to be rising